Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Infectious Disease Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Infectious Disease Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Exp Eye Res. 2021 Aug;209:108647. doi: 10.1016/j.exer.2021.108647. Epub 2021 Jun 5.
Bacterial infections of the cornea, or bacterial keratitis (BK), are notorious for causing rapidly fulminant disease and permanent vision loss, even among treated patients. In the last sixty years, dramatic upward trajectories in the frequency of BK have been observed internationally, driven in large part by the commercialization of hydrogel contact lenses in the late 1960s. Despite this worsening burden of disease, current evidence-based therapies for BK - including broad-spectrum topical antibiotics and, if indicated, topical corticosteroids - fail to salvage vision in a substantial proportion of affected patients. Amid growing concerns of rapidly diminishing antibiotic utility, there has been renewed interest in urgently needed novel treatments that may improve clinical outcomes on an individual and public health level. Bridging the translational gap in the care of BK requires the identification of new therapeutic targets and rational treatment design, but neither of these aims can be achieved without understanding the complex biological processes that determine how bacterial corneal infections arise, progress, and resolve. In this chapter, we synthesize the current wealth of human and animal experimental data that now inform our understanding of basic BK pathophysiology, in context with modern concepts in ocular immunology and microbiology. By identifying the key molecular determinants of clinical disease, we explore how novel treatments can be developed and translated into routine patient care.
细菌性角膜炎(BK),又称细菌性角膜感染,以迅速恶化、导致永久性视力丧失为特征,即使经过治疗也不例外。在过去的六十年里,BK 的发病率在国际上呈明显上升趋势,这在很大程度上是由于 20 世纪 60 年代末水凝胶隐形眼镜的商业化。尽管疾病负担日益加重,但目前针对 BK 的循证治疗方法——包括广谱局部抗生素,如果需要,还包括局部皮质类固醇——并不能使大部分受影响的患者挽救视力。由于对抗生素功效迅速下降的担忧日益加剧,人们重新关注急需的新型治疗方法,这些方法可能会提高个体和公共卫生水平的临床疗效。要想在 BK 的治疗中缩小转化差距,就需要确定新的治疗靶点和合理的治疗设计,但如果不了解决定细菌性角膜感染发生、进展和消退的复杂生物学过程,这两个目标都无法实现。在本章中,我们综合了目前大量的人类和动物实验数据,这些数据使我们能够深入了解 BK 的基本病理生理学,并结合现代眼免疫学和微生物学的概念。通过确定临床疾病的关键分子决定因素,我们探讨了如何开发新的治疗方法并将其转化为常规的患者护理。